David F. Steiner

David F. Steiner

Auto-generated profile, based on publicly available information

David F. Steiner

Google, Mountain View, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
WBWouter Bulten
Wouter Bulten
KKKimmo Kartasalo
Kimmo Kartasalo
PCPo-Hsuan Cameron Chen
Po-Hsuan Cameron Chen
PSPeter Ström
Peter Ström
HPHans Pinckaers
Hans Pinckaers
MEMartin Eklund
Martin Eklund
Artificial intelligence (AI) has shown promise for diagnosing prostate cancer in biopsies. However, results have been limited to individual studies, lacking validation in multinational settings. Competitions have been shown to be accelerators for medical imaging innovations, but their impact is hindered by lack of reproducibility and independent validation. With this in mind, we organized the PANDA challenge—the largest histopathology competition to date, joined by 1,290 developers—to catalyze development of reproducible AI algorithms for Gleason grading using 10,616 digitized prostate biopsies. We validated that a diverse set of submitted algorithms reached pathologist-level performance on independent cross-continental cohorts, fully blinded to the algorithm developers. On United States and European external validation sets, the algorithms achieved agreements of 0.862 (quadratically weighted κ, 95% confidence interval (CI), 0.840–0.884) and 0.868 (95% CI, 0.835–0.900) with expert uropathologists. Successful generalization across different patient populations, laboratories and reference standards, achieved by a variety of algorithmic approaches, warrants evaluating AI-based Gleason grading in prospective clinical trials.

1 December 2018 in American Journal of Surgical Pathology
Verified
Journal Article
Open access
DSDavid F. Steiner
David F. Steiner
RMRobert MacDonald
Robert MacDonald
YLYun Liu
Yun Liu
PTPeter Truszkowski
Peter Truszkowski
JHJason D. Hipp
Jason D. Hipp
MSMartin C. Stumpe
Martin C. Stumpe
Advances in the quality of whole-slide images have set the stage for the clinical use of digital images in anatomic pathology. Along with advances in computer image analysis, this raises the possibility for computer-assisted diagnostics in pathology to improve histopathologic interpretation and clinical care. To evaluate the potential impact of digital assistance on interpretation of digitized slides, we conducted a multireader multicase study utilizing our deep learning algorithm for the detection of breast cancer metastasis in lymph nodes. Six pathologists reviewed 70 digitized slides from lymph node sections in 2 reader modes, unassisted and assisted, with a wash-out period between sessions. In the assisted mode, the deep learning algorithm was used to identify and outline regions with high likelihood of containing tumor. Algorithm-assisted pathologists demonstrated higher accuracy than either the algorithm or the pathologist alone. In particular, algorithm assistance significantly increased the sensitivity of detection for micrometastases (91% vs. 83%, P=0.02). In addition, average review time per image was significantly shorter with assistance than without assistance for both micrometastases (61 vs. 116 s, P=0.002) and negative images (111 vs. 137 s, P=0.018). Lastly, pathologists were asked to provide a numeric score regarding the difficulty of each image classification. On the basis of this score, pathologists considered the image review of micrometastases to be significantly easier when interpreted with assistance (P=0.0005). Utilizing a proof of concept assistant tool, this study demonstrates the potential of a deep learning algorithm to improve pathologist accuracy and efficiency in a digital pathology workflow.

1 February 2020 in Radiology
Verified
Journal Article
Closed access
AMAnna Majkowska
Anna Majkowska
SMSid Mittal
Sid Mittal
DSDavid F. Steiner
David F. Steiner
JRJoshua Reicher
Joshua Reicher
SMScott Mayer McKinney
Scott Mayer McKinney
SSShravya Shetty
Shravya Shetty
Four deep learning models identified pneumothorax, fractures, opacity, and nodule or mass on frontal chest radiographs with similar performance to radiologists. BackgroundDeep learning has the potential to augment the use of chest radiography in clinical radiology, but challenges include poor generalizability, spectrum bias, and difficulty comparing across...

14 July 2021 in Communications Medicine
Verified
Journal Article
Open access
PDF file
PGPaul Gamble
Paul Gamble
RJRonnachai Jaroensri
Ronnachai Jaroensri
HWHongwu Wang
Hongwu Wang
FTFraser Tan
Fraser Tan
MMMelissa Moran
Melissa Moran
PCPo-Hsuan Cameron Chen
Po-Hsuan Cameron Chen
Background: Breast cancer management depends on biomarkers including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (ER/PR/HER2). Though existing scoring systems are widely used and well-validated, they can involve costly preparation and variable interpretation. Additionally, discordances between histology and expected biomarker findings can prompt repeat testing to address biological, interpretative, or technical reasons for unexpected results. Methods: We developed three independent deep learning systems (DLS) to directly predict ER/PR/HER2 status for both focal tissue regions (patches) and slides using hematoxylin-and-eosin-stained (H&E) images as input. Models were trained and evaluated using pathologist annotated slides from three data sources. Areas under the receiver operator characteristic curve (AUCs) were calculated for test sets at both a patch-level (>135 million patches, 181 slides) and slide-level (n = 3274 slides, 1249 cases, 37 sites). Interpretability analyses were performed using Testing with Concept Activation Vectors (TCAV), saliency analysis, and pathologist review of clustered patches. Results: The patch-level AUCs are 0.939 (95%CI 0.936–0.941), 0.938 (0.936–0.940), and 0.808 (0.802–0.813) for ER/PR/HER2, respectively. At the slide level, AUCs are 0.86 (95%CI 0.84–0.87), 0.75 (0.73–0.77), and 0.60 (0.56–0.64) for ER/PR/HER2, respectively. Interpretability analyses show known biomarker-histomorphology associations including associations of low-grade and lobular histology with ER/PR positivity, and increased inflammatory infiltrates with triple-negative staining. Conclusions: This study presents rapid breast cancer biomarker estimation from routine H&E slides and builds on prior advances by prioritizing interpretability of computationally learned features in the context of existing pathological knowledge.

2 November 2020 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
DSDavid F. Steiner
David F. Steiner
KNKunal Nagpal
Kunal Nagpal
RSRory Sayres
Rory Sayres
DFDavis J. Foote
Davis J. Foote
BWBenjamin D. Wedin
Benjamin D. Wedin
CMCraig H. Mermel
Craig H. Mermel
For patients with prostate cancer, the Gleason grade represents one of the most important factors in risk stratification and treatment.1-3 The current Gleason grade group (GG) system involves classification into 1 of 5 prognostic groups (GG1 through GG5, with higher GG indicating greater clinical risk) based on the relative amounts of Gleason patterns (ranging from 3 to 5, with 3 indicating low-grade carcinoma with well-formed glands and 5 indicating undifferentiated, or anaplastic, carcinoma) present. Despite its clinical importance, Gleason grading is highly subjective, with substantial interpathologist variability.4-9 Although urologic subspecialty–trained pathologists have been reported to have higher rates of concordance with each other as well as higher accuracy than general pathologists with regard to the risk stratification of patients,10-12 the number of urologic subspecialists is insufficient to review the large volume of prostate biopsies performed each year.

4 October 2022 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
RJRonnachai Jaroensri
Ronnachai Jaroensri
EWEllery Wulczyn
Ellery Wulczyn
NHNarayan Hegde
Narayan Hegde
TBTrissia Brown
Trissia Brown
IFIsabelle Flament-Auvigne
Isabelle Flament-Auvigne
PCPo-Hsuan Cameron Chen
Po-Hsuan Cameron Chen
Histologic grading of breast cancer involves review and scoring of three well-established morphologic features: mitotic count, nuclear pleomorphism, and tubule formation. Taken together, these features form the basis of the Nottingham Grading System which is used to inform breast cancer characterization and prognosis. In this study, we develop deep learning models to perform histologic scoring of all three components using digitized hematoxylin and eosin-stained slides containing invasive breast carcinoma. We first evaluate model performance using pathologist-based reference standards for each component. To complement this typical approach to evaluation, we further evaluate the deep learning models via prognostic analyses. The individual component models perform at or above published benchmarks for algorithm-based grading approaches, achieving high concordance rates with pathologist grading. Further, prognostic performance using deep learning-based grading is on par with that of pathologists performing review of matched slides. By providing scores for each component feature, the deep-learning based approach also provides the potential to identify the grading components contributing most to prognostic value. This may enable optimized prognostic models, opportunities to improve access to consistent grading, and approaches to better understand the links between histologic features and clinical outcomes in breast cancer.